• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Publication date: Available online 14 August 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurraySummaryBackgroundGlucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes reported. We aimed to synthesise the available evidence by doing a systematic review and meta-analysis of cardiovascular ou...
Source: The Lancet Diabetes and Endocrinology - August 15, 2019 Category: Endocrinology Source Type: research

Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies
Publication date: July 2018Source: The Lancet Diabetes & Endocrinology, Volume 6, Issue 7Author(s): L Gnatiuc, WG Herrington, J Halsey, J Tuomilehto, X Fang, HC Kim, D De Bacquer, AJ Dobson, MH Criqui, DR Jacobs, DA Leon, SAE Peters, H Ueshima, P Sherliker, R Peto, R Collins, RR Huxley, JR Emberson, M Woodward, S LewingtonSummaryBackgroundSeveral studies have shown that diabetes confers a higher relative risk of vascular mortality among women than among men, but whether this increased relative risk in women exists across age groups and within defined levels of other risk factors is uncertain. We aimed to determine whether ...
Source: The Lancet Diabetes and Endocrinology - July 10, 2018 Category: Endocrinology Source Type: research

Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980  793 adults from 68 prospective studies
Publication date: Available online 8 May 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Prospective Studies Collaboration and Asia Pacific Cohort Studies CollaborationLGnatiucWGHerringtonJHalseyJTuomilehtoXFangHCKimDDe BacquerAJDobsonMHCriquiDRJacobsJrDALeonSAEPetersHUeshimaPSherlikerRPetoRCollinsRRHuxleyJREmbersonMWoodwardSLewingtonNAokiHArimaEArnesenAAromaaGAssmannDLBachmanCBaigentHBartholomewABenetosCBengtssonDBennettCBjörkelundHBlackburnKBonaaEBoyleRBroadhurstJCarstensenLChamblessZChenSKChewRClarkeCCoxJDCurbRD'AgostinoCDateGDavey SmithGDe BackerSSDhaliwalXFDuanPDucimetiereSDuffyHEliassenPElwoodJEm...
Source: The Lancet Diabetes and Endocrinology - May 9, 2018 Category: Endocrinology Source Type: research

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
Publication date: Available online 6 December 2017 Source:The Lancet Diabetes & Endocrinology Author(s): M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Peter Öhman, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular...
Source: The Lancet Diabetes and Endocrinology - December 6, 2017 Category: Endocrinology Source Type: research

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
Publication date: Available online 13 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Rury R Holman, Ruth L Coleman, Juliana C N Chan, Jean-Louis Chiasson, Huimei Feng, Junbo Ge, Hertzel C Gerstein, Richard Gray, Yong Huo, Zhihui Lang, John J McMurray, Lars Rydén, Stefan Schröder, Yihong Sun, Michael J Theodorakis, Michal Tendera, Lynne Tucker, Jaakko Tuomilehto, Yidong Wei, Wenying Yang, Duolao Wang, Dayi Hu, Changyu Pan Background The effect of the α-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance is unknown....
Source: The Lancet Diabetes and Endocrinology - September 14, 2017 Category: Endocrinology Source Type: research

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
This study is registered with ClinicalTrials.gov, number NCT00700856. Findings Between Sept 18, 2008, and Jan 15, 2014, 3028 patients were randomly assigned and included in the analyses. 1535 were assigned to pioglitazone and 1493 to sulfonylureas (glibenclamide 24 [2%], glimepiride 723 [48%], gliclazide 745 [50%]). At baseline, 335 (11%) participants had a previous cardiovascular event. The study was stopped early on the basis of a futility analysis after a median follow-up of 57·3 months. The primary outcome occurred in 105 patients (1·5 per 100 person-years) who were given pioglitazone and 108 (1·5 per 100 person-yea...
Source: The Lancet Diabetes and Endocrinology - September 14, 2017 Category: Endocrinology Source Type: research

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
Publication date: Available online 29 July 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Cholesterol Treatment Trialists' (CTT) Collaboration Background Statin therapy is effective for the prevention of coronary heart disease and stroke in patients with mild-to-moderate chronic kidney disease, but its effects in individuals with more advanced disease, particularly those undergoing dialysis, are uncertain. Methods We did a meta-analysis of individual participant data from 28 trials (n=183 419), examining effects of statin-based therapy on major vascular events (major coronary event [non-fatal myoca...
Source: The Lancet Diabetes and Endocrinology - July 28, 2016 Category: Endocrinology Source Type: research

Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study
Publication date: Available online 7 May 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Christopher J D Wallis, Kirk Lo, Yuna Lee, Yonah Krakowsky, Alaina Garbens, Raj Satkunasivam, Sender Herschorn, Ronald T Kodama, Patrick Cheung, Steven A Narod, Robert K Nam Background Conflicting evidence exists for the association between testosterone replacement therapy and mortality and cardiovascular events. The US Food and Drug Administration recently cautioned that testosterone replacement therapy might increase risk of heart attack and stroke, based on evidence from studies with short treatment d...
Source: The Lancet Diabetes and Endocrinology - May 7, 2016 Category: Endocrinology Source Type: research

The changing face of diabetes complications
Publication date: Available online 4 May 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Edward W Gregg, Naveed Sattar, Mohammed K Ali The global increase in type 2 diabetes prevalence is well documented, but international trends in complications of type 2 diabetes are less clear. The available data suggest large reductions in classic complications of type 2 diabetes in high-income countries over the past 20 years, predominantly reductions in myocardial infarction, stroke, amputations, and mortality. These trends might be accompanied by less obvious, but still important, changes in the character of ...
Source: The Lancet Diabetes and Endocrinology - May 5, 2016 Category: Endocrinology Source Type: research

Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis
Publication date: Available online 6 February 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Rachel R Huxley , Sanne A E Peters , Gita D Mishra , Mark Woodward Background Studies have suggested sex differences in the mortality rate associated with type 1 diabetes. We did a meta-analysis to provide reliable estimates of any sex differences in the effect of type 1 diabetes on risk of all-cause mortality and cause-specific outcomes. Methods We systematically searched PubMed for studies published between Jan 1, 1966, and Nov 26, 2014. Selected studies reported sex-specific estimates of the standardised m...
Source: The Lancet Diabetes and Endocrinology - February 6, 2015 Category: Endocrinology Source Type: research